Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous dendritic cell immunotherapy in diabetic kidney disease
NCT06866158Phase 2Active, not recruiting
- Sponsor
- JES Kasih Nusantara Sejahtera
- Start
- May 2024
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in diabetic kidney disease (DKD), sponsored by JES Kasih Nusantara Sejahtera. Primary endpoint: Urine Albumin-Creatinine Ratio at 4 weeks. Started May 2024; status: active, not recruiting.
02
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06866158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866158.